Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in ...
Mainz Biomed partners with Thermo Fisher to develop advanced colorectal cancer screening tools while enhancing ColoAlert for ...
NV trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Benzinga Finance on MSN4d
Mainz Biomed $MYNZ & Thermo Fisher Partner On Next-Gen Colorectal Cancer Screening ProductMines Biomed, a molecular genetics diagnostic company, has entered into a collaborative agreement with Thermo Fisher ...
Mainz Biomed Announces Stock Split. BERKELEY, US and MAINZ, Germany – November 29, 2024 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular ...
In einem turbulenten Marktumfeld ist die Aktie von Mainz Biomed (NASDAQ: MYNZ) BV auf ein 52-Wochen-Tief von 0,18 US-Dollar gefallen. Dieser deutliche Rückgang spiegelt eine drastische Veränderung im ...
Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early ...
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics ...
and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. ( NASDAQ:MYNZ ) (“Mainz Biomed” or the“Company”), a molecular genetics diagnostic company specializing in the early ...
Fintel on MSN9d
HC Wainwright & Co. Downgrades Mainz Biomed N.V. (MYNZ)Fintel reports that on November 25, 2024, HC Wainwright & Co. downgraded their outlook for Mainz Biomed N.V. (NasdaqCM:MYNZ) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback